At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-dose, Randomized, Two-way, Two-period Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Subjects With Chronic Heart Failure
In Brief
A Phase 1 clinical trial evaluating Furosemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP, and 1 other intervention for Heart Failure. Completed, enrolled 20 participants across 1 site.
Signals
Detailed Summary
The proposed study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide. Although these regimens are not intended to be bioequivalent, they are both expected to achieve therapeutic plasma levels and induce effective diuresis. The test formulation in this study is a buffered solution, Furosemide Injection Solution at 30 mg/mL at pH 7.4 (range 7.0 to 7.8) and is intended for SC injection according to the instructions in the protocol. A commercial formulation of Furosemide Injection, USP will serve as the reference drug in this study, which will be administered by IV bolus. It contains furosemide 10 mg/mL in solution at alkaline pH of 8.0 to 9.3 and is marketed for IV and IM injection. The primary objective of the study is to estimate the absolute bioavailability of furosemide administered by subcutaneous infusion compared with an equivalent dose of furosemide administered by IV bolus administration.
Study Details
Timeline
Arms & Interventions
Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours
IV Furosemide Injection, USP (80 mg) by IV bolus
Interventions
Furosemide Injection Solution for subcutaneous administration (80 mg)
Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
Furosemide Injection Solution for subcutaneous administration (80 mg)